Filing Flows › Comparisons › ACUT vs YARW
Accustem Sciences vs Yarrow Bioscience: ACUT and YARW compared
Accustem Sciences is the larger company: $98K of revenue in its latest quarter (Q2 2026) against $97K for Yarrow Bioscience (Q2 2026).
Where the money goes: ACUT and YARW
Accustem Sciences (ACUT) · Q2 2026
Accustem Sciences, Q2 2026: revenue $98K, operating margin -256.7%, net loss $253K, operating cash flow −$249K. The chart follows the revenue to costs, profit and cash.
Yarrow Bioscience (YARW) · Q2 2026
Yarrow Bioscience, Q2 2026: revenue $97K (+41% year over year), net loss $3.0M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Accustem Sciences (ACUT) | Yarrow Bioscience (YARW) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $98K | $97K |
| Revenue growth, Y/Y | — | +41% |
| Operating margin | -256.7% | n/m |
| Net earnings | −$253K | −$3.0M |
| Net margin | -256.7% | — |
| Operating cash flow | −$249K | −$2.0M |
Questions
Which is bigger, Accustem Sciences or Yarrow Bioscience?
Accustem Sciences is the larger company: $98K of revenue in its latest quarter (Q2 2026) against $97K for Yarrow Bioscience (Q2 2026).
More: Accustem Sciences earnings · how Accustem Sciences makes money · Yarrow Bioscience earnings · how Yarrow Bioscience makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.